The Rising Importance of Real-World Evidence in Pharma

The pharmaceutical industry is experiencing a transformative shift in how clinical and commercial decisions are made. Real-world evidence solutions are projected to grow from approximately $5.43 billion in 2025 to $10.83 billion by 2030, reflecting the critical role RWE now plays across the drug development lifecycle. Real-world evidence, derived from data collected outside traditional clinical trials, offers pharmaceutical companies unprecedented insights into how treatments perform in everyday clinical settings, making it indispensable for regulatory approvals, market access, and post-market surveillance.

The growing acceptance of RWE from regulators, payers, prescribers, and patients creates new possibilities for demonstrating product value, while addressing the industry's need to reduce R&D costs that often exceed $2 billion per drug. As healthcare systems increasingly adopt value-based care models, pharmaceutical consulting companies specializing in real-world evidence have become strategic partners for life sciences organizations seeking competitive advantage.

Why Pharmaceutical Companies Need RWE Consulting

The complexity of modern healthcare data ecosystems requires specialized expertise. Pharmaceutical and biotechnology companies lead the RWE solutions market adoption, driven by the need to optimize drug development, facilitate regulatory approvals, improve market access, and track post-market outcomes. Professional consulting firms bring critical capabilities that internal teams often lack:

Data Integration and Analytics: RWE consultants possess advanced analytics platforms that can integrate diverse data sources, including electronic health records, insurance claims, patient registries, wearables, and genomic data. This integration enables comprehensive patient journey mapping and treatment outcome analysis.

Regulatory Expertise: The FDA's RWE program now permits sponsors to interact with regulators early regarding RWE protocols, with the proportion of FDA approvals containing RWE increasing from roughly 5-10% to nearly 50% between 2020 and 2024. Consulting firms navigate these evolving regulatory landscapes, ensuring study designs meet regulatory standards.

Health Economics and Market Access: Payers increasingly demand real-world evidence to support reimbursement decisions. Consulting companies help pharmaceutical firms build compelling health economic models and value propositions that resonate with diverse stakeholder groups.

Accelerated Timelines: Use of RWE has led to a 40% reduction in planned sample sizes for pivotal phase III programs, translating into six months of time savings, demonstrating how expert RWE application can significantly compress development timelines.

Top 10 Pharmaceutical Consulting Companies Leveraging Real-World Evidence

1. IQVIA

IQVIA is recognized as the leader in Real World Evidence and Real World Data solutions, operating in over 100 countries. The company combines unparalleled clinically rich health data with advanced analytics and deep therapeutic expertise. IQVIA's Real World Solutions team supports pharmaceutical companies throughout the product lifecycle, offering capabilities ranging from retrospective cohort studies to prospective registries and pragmatic trials. Their dedicated real-world evidence operations teams are trained for both traditional and innovative study designs, with robust quality management standards integrated into operational processes.

Key Strengths: Comprehensive global data networks, AI-powered analytics, end-to-end medical affairs solutions, and established relationships with regulatory agencies worldwide.

2. Optum (UnitedHealth Group)

Optum provides RWE solutions through its Optum Insight segment, enabling healthcare systems to manage costs, adhere to compliance requirements, enhance clinical performance, and navigate the dynamic healthcare landscape. As part of UnitedHealth Group, Optum possesses unique access to extensive claims data and healthcare delivery insights. The company serves payers, care providers, employers, governments, life science companies, and consumers across 150 countries.

Key Strengths: Extensive claims database access, payer insights, population health management expertise, and integrated healthcare delivery perspectives.

3. Parexel International

Established in 1982, Parexel is a global contract research organization specializing in clinical research, consulting, and technology solutions for pharmaceutical, biotechnology, and medical device sectors. Parexel's real-world evidence capabilities support clients in generating evidence for regulatory submissions, pharmacovigilance, market access, and commercial strategy. The company operates in multiple countries and has developed sophisticated platforms for real-world data analysis.

Key Strengths: Global clinical research infrastructure, regulatory consulting expertise, pharmacovigilance capabilities, and established therapeutic area specialization.

4. DelveInsight

DelveInsight stands out as a specialized business consulting and market research firm with deep expertise in the life sciences sector. DelveInsight provides comprehensive real-world evidence solutions that support pharmaceutical and biotechnology companies in optimizing drug development, facilitating regulatory approvals, improving market access, and tracking post-market outcomes. The company's approach integrates patient journey consulting, health economics and outcomes research (HEOR), and advanced market intelligence.

DelveInsight leverages real-world evidence to demonstrate value and inform decision-making, conducting health economic and outcomes research to showcase cost-effectiveness while gathering RWE to support clinical and economic value. With over 15 years of experience and a repository of more than 7,000 research reports covering 27+ therapeutic areas, DelveInsight offers personalized, integrated market solutions. The firm's competitive intelligence services provide real-time insights into clinical, regulatory, and commercial developments, helping clients maintain strategic advantage.

Key Strengths: Specialized pharma focus, extensive therapeutic area coverage, patient journey mapping, KOL networks, customized market research, and epidemiology-driven forecasting capabilities.

5. Flatiron Health (Roche)

Flatiron Health specializes in oncology-focused real-world evidence, utilizing one of the industry's largest oncology-specific databases. Flatiron Health renewed its collaboration with the National Comprehensive Cancer Network to maintain the NCCN Quality & Outcomes Database, a cloud-based repository of cancer treatment data. The company's technology platform enables cancer centers to learn from every patient, improving care delivery while generating valuable insights for pharmaceutical companies.

Key Strengths: Oncology specialization, high-quality curated data, regulatory-grade evidence generation, and direct connections to cancer treatment centers.

6. ICON plc

Based in Dublin, Ireland, ICON provides specialized services in clinical research and drug development, offering clinical trial management, data management, laboratory support, and strategic consultancy. The company's real-world evidence capabilities include patient-level linked data assets that support analysis across the patient journey. In March 2025, ICON launched PatientSourceDuo, providing linked healthcare claims data for research and commercial evidence strategies.

Key Strengths: Global clinical research operations, therapeutic area expertise, technology platforms, and patient-centered data assets.

7. Aetion

Aetion represents a new generation of RWE technology platforms, offering cloud-based analytics that enable rapid evidence generation. Aetion has united with other industry stakeholders to expand the use of RWE among pharmaceutical, device, and regulatory parties. The company's platform is designed to meet regulatory standards while providing real-time insights from diverse data sources.

Key Strengths: Modern cloud-based platform, regulatory-grade methodology, user-friendly interface, and focus on causal inference analytics.

8. Syneos Health

Syneos Health positions itself as the only fully integrated biopharmaceutical solutions organization, combining clinical development capabilities with commercial expertise. The company's real-world evidence services support both pre-approval evidence generation and post-launch commercial strategy. Syneos Health operates globally with deep therapeutic area knowledge.

Key Strengths: Integrated clinical and commercial capabilities, biopharmaceutical focus, global reach, and therapeutic specialization.

9. Medidata Solutions (Dassault Systèmes)

Medidata Solutions specializes in cloud-based solutions for clinical research with strong focus on real-world evidence, artificial intelligence, and data-driven insights. The company's platforms streamline data collection, storage, and access while enabling sophisticated analytics. Medidata's technology infrastructure supports both traditional clinical trials and real-world studies.

Key Strengths: Cloud-based technology platform, AI capabilities, clinical trial expertise, and integration with broader Dassault Systèmes ecosystem.

10. Oracle (Oracle Health Sciences)

Oracle brings enterprise-scale technology and data management capabilities to real-world evidence generation. The company's health sciences division offers comprehensive solutions for clinical development, pharmacovigilance, and real-world analytics. Oracle's platforms enable integration of diverse data sources with robust security and compliance features.

Key Strengths: Enterprise technology infrastructure, data security, regulatory compliance capabilities, and global implementation support.

Key Trends Shaping the RWE Consulting Landscape

Artificial Intelligence and Machine Learning Integration

AI-powered analytics are transforming real-world data into instant, actionable insights for regulatory and commercial success, with machine learning models enabling better patient stratification and treatment outcome forecasting. Leading consulting firms are investing heavily in AI capabilities to deliver more sophisticated predictive analytics.

Regulatory Evolution

Regulatory agencies worldwide are formalizing RWE acceptance. The FDA and EMA are formally adopting RWE for approvals and safety monitoring, challenging conventional trial methods and increasing demand for validated, regulatory-grade platforms. This evolution creates opportunities for consulting firms with regulatory expertise.

Value-Based Healthcare Transformation

The global shift toward value-based healthcare is shifting decision-making authority from pharma to payers, disrupting evidence strategies and boosting reliance on RWE for cost-effectiveness and reimbursement negotiations. Consulting companies must help pharmaceutical clients develop compelling economic arguments backed by real-world evidence.

Data Source Proliferation

Healthcare data now encompasses electronic health records across provider organizations, pharmacy claims, genomics testing, and patient demographic data, with vendors exploring computer-assisted mining of clinical notes and synthetic data. Managing this complexity requires sophisticated data integration capabilities.

Selecting the Right RWE Consulting Partner

When evaluating RWE consulting firms, pharmaceutical executives should consider several critical factors:

Therapeutic Area Expertise: Does the consulting firm have deep experience in your specific disease areas? Oncology and rare diseases have become the largest and fastest growing therapeutic areas for RWE application due to their complexity.

Data Access and Quality: What proprietary data assets does the firm control? How do they ensure data quality and regulatory compliance?

Technology Platform Capabilities: Cloud-based platforms that integrate EHRs, claims data, and real-world patient insights will separate winners from laggards. Assess the firm's technology infrastructure and analytics capabilities.

Regulatory Track Record: Has the consulting firm successfully supported regulatory submissions using real-world evidence? What relationships do they maintain with regulatory agencies?

Global Reach: For international development programs, consider firms with established operations in key markets and understanding of regional regulatory requirements.

Collaborative Approach: The best consulting partners work collaboratively with internal teams, transferring knowledge while delivering results.

The Future of RWE in Pharmaceutical Development

Real-world evidence has evolved from a post-marketing surveillance tool to a strategic asset deployed throughout the product lifecycle. RWE solutions help stakeholders understand how medical products perform in everyday clinical settings, supporting regulatory decision-making, enhancing drug development strategies, and facilitating value-based care.

The consulting firms leading this transformation combine deep scientific expertise with advanced technology platforms and regulatory acumen. As the industry continues its shift toward personalized medicine and value-based care, partnerships with specialized RWE consulting companies will become increasingly critical for pharmaceutical success.

For pharmaceutical executives, biotech leaders, and healthcare investors, selecting the right RWE consulting partner represents a strategic decision with long-term implications for product development, regulatory success, and commercial performance. The companies profiled in this article represent the current leaders in this rapidly evolving field, each bringing unique strengths to address the complex challenges of modern pharmaceutical development.

Conclusion

The real-world evidence revolution is reshaping pharmaceutical development, regulatory approval processes, and market access strategies. The consulting companies highlighted here—from established global leaders like IQVIA and Optum to specialized firms like DelveInsight and innovative platforms like Aetion—are driving this transformation. By partnering with these expert organizations, pharmaceutical companies can navigate regulatory complexity, accelerate development timelines, strengthen market access, and ultimately deliver better outcomes for patients.